Panacea Biotec Announces Special Window for Share Transfer & Dematerialization
Panacea Biotec opens a special window from Feb 05, 2026, to Feb 04, 2027, for facilitating transfer and dematerialization of physical shares. This is for investors who sold/purchased shares before April 01, 2019, and faced issues with transfer lodgement.
This is a procedural announcement related to share transfers and dematerialization for a specific set of shareholders, with no immediate direct financial impact on the company or its operations.
The announcement is a routine compliance filing regarding a special window for share transfer and dematerialization, providing procedural information without significant financial or operational impact.
Panacea Biotec Limited has announced the opening of a special window for a period of one year, from February 05, 2026, to February 04, 2027. This initiative is in accordance with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026.
The special window is designed to facilitate the lodgement or re-lodgement of transfer requests for physical shares. It is specifically for investors who sold or purchased physical shares before April 01, 2019, and either had not lodged the shares for transfer or had lodged them but they were rejected, returned, or not attended to due to documentation deficiencies.
Eligible investors are advised to submit their requests for transfer and dematerialization of shares, along with original share certificates and other required documents, to the Company's Registrar and Share Transfer Agent, M/s Skyline Financial Services Pvt. Ltd., located at 1st Floor, D-153/A, Pocket D, Okhla Phase I, Okhla Industrial Estate, New Delhi-110020. Investors can also reach out via email at <email> or call on 011-40450193-97 within the stipulated period. Shareholders are also requested to update their email IDs with the Company or RTA/Depository Participants.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under share transfer updates. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.